Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Myriad Genetics (MYGN) Tops Q4 EPS by 5c; Raises Outlook

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2018 Financial Results

August 21, 2018 4:05 PM EDT

Total Fourth-Quarter Revenues of $200.9 MillionFourth-Quarter Diluted EPS of $0.18 and Adjusted EPS of $0.38, Up 31 Percent

SALT LAKE CITY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal fourth-quarter and full-year 2018, provided an update on recent business highlights and issued its fiscal year and first-quarter 2019 financial guidance.

"Fiscal year 2018 was an excellent year for Myriad as record-setting growth in new products with increasing reimbursement added to a solid hereditary cancer business and a... More